We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
293 50 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
293>> AFM26 cd16a partnership disclosed........ Roche doing the preclinical..scaram(o)uche-May 20
292AFM26 cd16a partnership disclosed because of upcoming meeting. Roche doing the semi_infinite -May 17
291That's where all the fun is! And the $$$MiroSI-January 28
290I guess you are right.Crueldog-January 26
289They all moved to stocktwits… lolyofal-January 21
288what happened to this board. tril has busted loose and conversation ended.Crueldog-January 20
287I think so ;-)yofal-January 2
286FTSV is, without doubt, a better run company. Like LOXO vs BPMC. But there areClarksterh-12/31/2019
285It has had quite a run already. A run that's based upon FTSV data.semi_infinite -12/31/2019
284Does anyone here think TRIL is a buy? BladerunnerBladerunner17-12/30/2019
283If I had bought TRIL a few weeks ago at $.30, as a friend suggested, I would havBladerunner17112/26/2019
282FTSV - CC later today after ASH sessions. ir.fortyseveninc.comsemi_infinite -12/9/2019
281Oddly, Trillium has made no announcement of this licensing deal from yesterday. tuck-9/26/2019
280Stanford - cd47 is not the complete solution. med.stanford.edusemi_infinite -8/1/2019
279Another approach to CD47. nature.comsemi_infinite 17/3/2019
278Wow. I wonder what it could do in earlier interventions, or even if that is waratticus4paws-6/13/2019
277AFMD - AFM13 combo with Pembro continues to impress. onlinelibrary.wiley.comsemi_infinite -6/13/2019
276Tweet regarding Forty-Seven's updated results (which aren't being receivtuck-5/16/2019
275"It will some time and some more dilution before they have much to show anysemi_infinite -4/30/2019
274So Dr. Stiernholm is out, and Dr. Uger takes the helm for the moment. Share prituck-4/30/2019
273Arch gets funding for ph 1 trial. businesswire.comsemi_infinite -3/26/2019
272>>Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPa axis and tuck-3/5/2019
271Good idea to see if all time low at 0.48 holds. IMO it gets tested at the leastsemi_infinite -3/1/2019
270No rush on my side. Too many mistakes.Miljenko Zuanic-2/28/2019
26920+ abstracts at AACR when cd47 used in search. Interesting one from Arch Onco semi_infinite -2/28/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):